Abstract IA02: Direct targeting of the intrinsically disordered transactivation domain of androgen receptor enables transcriptome-selective pharmacology
Androgen receptor (AR) is a therapeutic target for prostate cancer. Despite effective drugging its folded ligand-binding domain (LBD), resistance will develop by mechanisms involving reactivation of AR signaling. These mechanisms include expression of constitutively active AR that lacks LBD such as AR-V7 which fueled...